Based on NIH | In people with head and neck cancer, can persistent heart palpitations be a symptom or a treatment-related side effect, and how should they be evaluated?

Persistent heart palpitations in people with head and neck cancer can arise from both the cancer itself and from cancer treatments, and they warrant a careful, structured evaluation. In many cases, palpitations are linked to treatment-related effects such as chemotherapy (for example 5‑fluorouracil and platinum agents), immunotherapy (for example pembrolizumab), radiation effects, or indirect contributors like anemia, thyroid dysfunction, dehydration, infection, pain, anxiety, and electrolyte disturbances. ^{[1] [2]} Palpitations can also be a warning sign of more serious heart problems, including abnormal rhythms, myocarditis (heart inflammation), or ischemia (reduced blood flow), particularly during or after oncologic therapy. ^{[1] [2]}

Why palpitations happen in this setting

• Chemotherapy (5‑fluorouracil/capecitabine): These agents can provoke coronary artery spasm and arrhythmias; symptoms often appear within days of infusion and may include chest pain, ECG changes, and irregular heartbeat. ^{[3] [4]} Cardiotoxicity has been observed in patients receiving 5‑fluorouracil with cisplatin for head and neck and related cancers, with arrhythmias among the most common findings. ^[5]

• Platinum agents (cisplatin/carboplatin): Electrolyte losses (especially magnesium and potassium) from nephrotoxicity can predispose to arrhythmias and QT prolongation; regular electrolyte checks and supplementation are typically advised. ^{[6] [7]} Maintaining potassium above 4.0 mmol/L and magnesium above 0.8 mmol/L during high‑risk therapies is often recommended to reduce rhythm risk. ^[8]

• Immunotherapy (pembrolizumab): Immune checkpoint inhibitors can rarely cause myocarditis, cardiomyopathy, pericarditis, and arrhythmias; early recognition is crucial due to potentially rapid progression. ^{[9] [10]} Product safety information lists arrhythmia and myocarditis among reported serious adverse events. ^{[11] [12]}

• Radiation therapy: Radiation involving the thorax or areas near the heart can, over time, lead to radiation‑induced cardiac disease, which may include pericarditis, myocarditis, coronary disease, and arrhythmias; manifestations range from acute to late effects. ^{[13] [14]}

• Endocrine effects of therapy: Immunotherapy can trigger thyroiditis leading to hyperthyroidism (fast heartbeat, heat intolerance, anxiety) or hypothyroidism, both of which can cause palpitations or rhythm changes. ^{[15] [16]}

• General cardio‑oncology considerations: Cancer therapies across classes can raise arrhythmia risk, and evaluation of palpitations should be comparable to the general population with additional attention to treatment‑specific risks and complications. ^{[17] [18]} Palpitations are frequent in people with cancer and may have arrhythmic and non‑arrhythmic causes that need tailored assessment. ^[19]

Red flags that need urgent care

• Chest pain, shortness of breath, fainting/near‑fainting, or a sustained racing/irregular heartbeat during or after treatment should prompt immediate medical attention or emergency evaluation, as recommended in patient guidance for head and neck cancer regimens that include chemotherapy and immunotherapy. ^{[20] [21]} Patient education materials emphasize telling the care team right away or going to the emergency department for these symptoms during chemotherapy or immunotherapy. ^{[22] [23]}

How palpitations should be evaluated

A practical evaluation pathway integrates standard palpitation work‑up with cardio‑oncology nuances:

1. History and symptom timing

• Link symptoms to treatment cycles (for example, days 2–5 after 5‑fluorouracil), infusion days, or new immunotherapy doses; note triggers such as dehydration or infection. ^{[3] [1]} Ask about chest pain, dyspnea, presyncope/syncope, fever, and thyroid‑like symptoms (heat intolerance, tremor, anxiety). ^{[20] [15]}

2. Physical exam and vitals

• Assess blood pressure, heart rate, oxygen saturation, signs of fluid overload, and fever. Persistent tachycardia with other symptoms increases concern for myocarditis or arrhythmia in the treatment context. ^{[1] [9]}

3. Baseline tests

• 12‑lead ECG to detect arrhythmia, conduction changes, or QT prolongation; QT monitoring is particularly relevant when agents or electrolyte shifts increase torsades risk. ^{[24] [18]}
• Laboratory tests: complete blood count (for anemia or infection), comprehensive metabolic panel with magnesium and potassium (cisplatin‑related wasting), thyroid‑stimulating hormone/free T4 (immune‑related thyroiditis), troponin and BNP if myocarditis or heart strain is suspected. ^{[6] [15]} Routine electrolyte monitoring and correction are recommended with cisplatin‑based regimens to reduce arrhythmia risk. ^[7]

4. Cardiac imaging and rhythm monitoring

• Echocardiogram if there is dyspnea, elevated biomarkers, new murmurs, or suspected myocarditis/heart failure. ^[2] Ambulatory monitoring (Holter/event monitor 24 hours to 2 weeks) can capture intermittent arrhythmias if the ECG is non‑diagnostic. ^[25]

5. Treatment‑specific considerations

• 5‑fluorouracil/capecitabine: If chest pain or arrhythmia occurs, clinicians often discontinue the drug and evaluate for coronary spasm or ischemia; recurrence is common on re‑challenge and dose reduction may not prevent it. ^{[3] [5]}
• Cisplatin/carboplatin: Check and replace magnesium and potassium consistently; monitor QT if other QT‑prolonging risks exist. ^{[6] [24]}
• Immunotherapy (pembrolizumab): If myocarditis is suspected (palpitations with chest pain, dyspnea, elevated troponin/ECG changes), early cardiology involvement and immune‑related toxicity protocols are typically initiated because outcomes improve with prompt treatment. ^{[9] [10]}
• Radiation: Consider radiation‑related heart disease in those with prior chest/mediastinal exposure who present with arrhythmias, even late after therapy. ^[13]

6. Multidisciplinary care

• Cardio‑oncology programs and collaboration between oncology and cardiology help tailor monitoring (for example baseline/interval ECGs, echocardiograms) and management during and after treatment. ^[26] Coordinated care supports safe continuation or adjustment of cancer therapy while addressing cardiovascular safety. ^[1]

Practical self‑care and prevention tips

• Stay well hydrated, especially around chemotherapy days, to help maintain stable blood pressure and minimize electrolyte shifts. ^[1]
• Keep track of palpitations with timing relative to treatment; share a symptom log with your care team to identify patterns that align with specific drugs. ^[19]
• Ensure scheduled lab checks are completed; replacing low magnesium or potassium can reduce rhythm irritability, particularly with platinum therapy. ^{[6] [8]}
• Report new thyroid‑type symptoms promptly (for example, heat intolerance, tremor, fast heartbeat), as simple blood tests can detect therapy‑related thyroiditis that is treatable. ^{[15] [16]}
• Seek urgent help for chest pain, shortness of breath, fainting, or a sustained fast/irregular heartbeat during treatment. ^{[20] [22]}

---

Summary table: common therapy links to palpitations and suggested checks

Therapy/Factor	Possible mechanism for palpitations	Typical timing/pointers	Key evaluations
5‑Fluorouracil/capecitabine	Coronary vasospasm, ischemia, arrhythmia	Often days 2–5 of infusion; chest pain, ECG changes	ECG, troponin, stop agent if suspected; cardiology review; high recurrence on re‑challenge
Cisplatin/carboplatin	Electrolyte wasting (Mg, K), QT prolongation	During cycles; worsens with dehydration/renal dysfunction	CMP with Mg/K each cycle; ECG if symptoms/QT risk; replace electrolytes
Pembrolizumab (ICIs)	Myocarditis, arrhythmias, pericarditis	Any time after start; may be early; can progress quickly	ECG, troponin, BNP, echo; consider immune‑related myocarditis pathway; cardiology
Radiation (thoracic exposure)	Pericarditis, coronary disease, arrhythmias	Acute or late (months–years)	ECG, echo, ischemia evaluation as indicated
Thyroid dysfunction (immune‑related)	Hyperthyroidism → tachycardia; hypothyroidism → rhythm changes	Weeks to months after ICI start	TSH/free T4; manage thyroiditis
General chemotherapy effects	Direct cardiotoxicity causing fast/irregular beats	Variable; during treatment	Consider baseline and interval heart tests when risk is known

---

Take‑home message

• Persistent palpitations in head and neck cancer can be due to the disease or to treatments such as chemotherapy, immunotherapy, or radiation, as well as common contributors like anemia, thyroid changes, dehydration, infection, and electrolyte imbalances. ^{[1] [2]} Because some causes are potentially serious but treatable, a focused evaluation history and timing relative to therapy, ECG, labs (including magnesium, potassium, thyroid tests), and selective imaging/monitoring is recommended, with early involvement of cardio‑oncology when red flags or high‑risk treatments are present. ^{[19] [24]} When concerning symptoms occur during treatment (chest pain, shortness of breath, fainting, sustained racing heartbeat), users are generally advised to alert the care team immediately or go to emergency care. ^{[20] [21]}